Replicate Bioscience

About:

Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform.

Website: https://replicatebioscience.com/

Twitter/X: Replicate_Inc

Top Investors: Apple Tree Partners

Description:

Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

Total Funding Amount:

$46M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)replicatebioscience.com

Founders:

Andrew Geall, Herbert Kim Lyerly, Nathaniel Wang, Zachary Hartman

Number of Employees:

11-50

Last Funding Date:

2021-09-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai